NEW YORK (GenomeWeb News) – Transgenomic today reported that its first-quarter revenues fell 21 percent year over year, and the firm swung to a loss from a profit a year earlier.

The Omaha, Neb.-based pharmacogenomics firm brought in revenues of $5 million for the three-month period ended March 31, compared to $6.3 million for the first quarter of 2008.

"Unfortunately, like many companies today, we are also experiencing an impact from the overall economic slowdown," Transgenomic President and CEO Craig Tuttle said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.